The FDAnews Webinar Training Pass program offers year-round, unrestricted access to any of the hundreds of webinars listed below. These training programs feature thought leadership and best practices from top consultants, expert speakers and current and former FDA officials. New webinars are offered every month, along with access to the Webinar Training Pass archive.
BUY NOW Single-User 1-Year Unlimited Access $1,362
If you are already a Training Pass member, login below and then scroll down to view the list in date order or narrow your search by keyword or category. Viewing the webinar is easy… simply identify the webinar you want to watch, click on the title and the video will begin. If you would like to view or download the presentation materials separately from the video, click the "Download Presentation" link.
Also available: Take advantage of our multi-user and site licenses of the Webinar Training Pass, so you’ll have the most-informed workforce! Contact Russ Titsch, Business Development Director at russ.titsch@wcgclinical.com or +1 703.538.7651 to receive a custom quote.
Search by keyword, speaker name or just by category (drug, device or clinical) and you'll find all you need.
If you have any questions or are having any problems please give us a call on 703.538.7600 or email customer service.
Webinar Training Pass
Recorded on: April 18, 2019
Description:Dan Matlis and Mike Jovanis discuss the application of modern technologies to product lifecycle management. They cover:
- ICH Q12 and its potential benefits;
- How technology can support ICH Q12 and simplify change management; and
- Innovative ways leading pharma companies are addressing PACM.
Presentation: Download the presentation
Transcript: Download the transcript
Speakers: Daniel R. Matlis, Founder and President, Axendia, and Mike Jovanis, VP-Vault Quality, Veeva Systems
Recorded on: April 4, 2019
Description: Quality systems expert Dan O’Leary explains the hybrid system where you maintain a device certificate under the MDD and a QMS under the MDR. He discusses:
- The dates from the EU-MDR for when the hybrid system can apply;
- The three elements from the MDR Chapter VII – post-market surveillance, market surveillance and vigilance;
- The role of device registration and the required data elements; and
- How to structure the technical documentation for the hybrid system.
Presentation: Download the presentation
Transcript: Download the transcript
Speaker: Dan O’Leary, President, Ombu Enterprises LLC
Recorded on: March 29, 2019
Description: IRB official Kristin J. Craun clarifies key aspects of the revised Common Rule and approaches for educating research teams and ensuring compliance. She discusses:
- How new exempt categories may reduce obligations in human subject protection;
- How new required elements of consent change the standards for informing patients and obtaining consent;
- How the use of continuing review policies apply to minimal risk research and its effect on daily responsibilities in managing clinical trials; and
- How the new Common Rule requirement allows flexibility in some clinical trial areas and the key factors in determining when and how this flexibility can be utilized.
Presentation: Download the presentation
Transcript: Download the transcript
Speaker: Kristin J. Craun, Senior Director, Institutional Review Board, University of Southern California
Note: Due to technical issues, the first 2 minutes of this recording is missing.
Recorded on: March 28, 2019
Description: Cell and gene therapy expert Scott R. Burger discusses the FDA’s requirements for biologics license applications, common mistakes applicants make and how to avoid them. He covers:
- How a cell or gene therapy BLA fits into the framework of the CTD;
- What reviewers in the Office of Tissues and Advanced Therapies expect to see in a BLA; and
- How the earlier stages of development affect the content of the BLA.
Presentation: Download the presentation
Transcript: Download the transcript
Speaker: Scott R. Burger, Principal, Advanced Cell and Gene Therapy
Recorded on: March 26, 2019
Description: Research integrity expert Donna Kesslier discusses the increased focus on the reliability of research data, honesty in reporting and data reproducibility in an era of heightened competition and pressure. She covers:
- How regulatory authorities are defining research misconduct;
- What are questionable research practices (QRPs), especially in dealing with vulnerable populations; and
- Tips for compliance in conducting proper research in the areas of subject recruitment, consent, recordkeeping and patient outreach and communication.
Presentation: Download the presentation
Transcript: Download the transcript
Speaker: Donna Kesslier, Research Integrity Officer, Duke University
Recorded on: March 25, 2019
Description: Patient centricity advocates Maggie Buckley, Pamela Bennett and Danya Kaye discuss how to improve clinical trials by involving patients in recruitment efforts, consent agreements, educational materials and engagement. Topics include:
- Things to consider before beginning a patient engagement program;
- Ways to engage directly with patients as advisors; and
- Elements necessary to engage patients and patient advocacy organizations in clinical trial development and treatment.
Presentation: Download the presentation
Transcript: Download the transcript
Speakers: Maggie Buckley, Volunteer Patient Advocate; Pamela Bennett, Executive Healthcare and Corporate Affairs Consultant; and Danya Kaye, Director of Business Development, R&D and Innovation, Inspire
Recorded on: March 22, 2019
Description: Regulatory expert Lynn Mehler addresses the FDA’s expectations for REMS assessment. She discusses:
- How REMS assessments have changed in the past decade;
- How REMS assessments can lead to additional requirements, separate and apart from modifications to a REMS; and
- How to use REMS assessments to build a case for REMS modification, including elimination of requirements.
Presentation: Download the presentation
Transcript: Download the transcript
Speaker: Lynn Mehler, Partner, Hogan Lovells
Recorded on: March 21, 2019
Description: Attorney Jessica Ringel discusses how the FDA will prioritize its regulatory efforts in 2019, including:
- Recent revisions to the medical device guidance and activities required by the FDA Reauthorization Act (FDARA);
- Nuances pertaining to quality and regulatory professionals included in CDRH’s FY 2019 guidance agenda; and
- Status of the ever-evolving voluntary FDA pilot programs.
Presentation: Download the presentation
Transcript: Download the transcript
Speaker: Jessica Ringel, Counsel, King & Spalding
Recorded on: March 20, 2019
Description: : Pediatric trial experts Lisa Benson and Janelle Allen discuss how to deal with the differences and challenges faced while conducting pediatric clinical trials. Topics include:
- How to develop study budgets specific to pediatric clinical trials, including recruitment and administrative costs;
- Approaches to recruitment in pediatric research, including the pros and cons of using different forms of standard and social media;
- How to identify the challenges faced when conducting pediatric clinical trials; and
- Strategies for successful retention of children in clinical trials.
Presentation: Download the presentation
Transcript: Download the transcript
Speakers: Lisa Benson, Senior Vice President of Research, Education and Quality, and Janelle Allen, Director of Research, Education and Quality for the Institute of Advanced Clinical Trials for Children
Recorded on: March 19, 2019
Description: Medical device expert J. Lawrence Stevens discusses trends in the FDA’s regulation of integrated devices. He covers:
- FDA premarket and postmarket requirements for medical imaging devices;
- How to interpret and comply with the FDA’s imaging guidance; and
- The agency’s plans for future medical imaging regulation.
Presentation: Download the presentation
Transcript: Download the transcript
Speaker: J. Lawrence Stevens, Principal Consultant, One Way Consultants, LLC